- Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia. 2017 In Process GET IT
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial. The Lancet Oncology. 2016 Academic Article GET IT
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
British journal of haematology.
Times cited: 11
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Times cited: 75